| 2026-08-10 | Presentation | Corporate Presentation |
| 2026-08-10 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 |
| 2026-06-23 | Press release | Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for |
| 2026-06-18 | Press release | Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respir |
| 2026-05-28 | Press release | Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
| 2026-05-11 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 |
| 2026-05-04 | Press release | Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American |
| 2026-04-13 | Press release | Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT I |
| 2026-04-07 | Press release | Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the |
| 2026-03-30 | Press release | Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the Ame |
| 2026-03-03 | Press release | Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference |
| 2026-02-10 | Press release | Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Ty |
| 2026-02-09 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 |
| 2026-01-08 | Press release | Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook |
| 2026-01-05 | Press release | Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-11-17 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 |
| 2025-11-04 | Press release | Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2025-10-20 | Press release | Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, |
| 2025-10-07 | Press release | Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of R |
| 2025-10-02 | Press release | Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwri |
| 2025-09-30 | Press release | Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 2025-09-30 | Press release | Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock |
| 2025-09-29 | Presentation | View Presentation |
| 2025-09-29 | Press release | Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Resp |
| 2025-09-26 | Press release | Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Re |
| 2025-09-03 | Press release | Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Of |
| 2025-08-21 | Press release | Enanta Pharmaceuticals to Participate in September Investor Conferences |
| 2025-08-20 | Press release | Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union |
| 2025-08-11 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 |
| 2025-08-05 | Press release | Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series |
| 2025-07-15 | Press release | Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series |
| 2025-06-11 | Press release | Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pi |
| 2025-05-27 | Press release | Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
| 2025-05-22 | Press release | Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus |
| 2025-05-12 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 |
| 2025-04-08 | Press release | Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 |
| 2025-03-17 | Press release | Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference |
| 2025-03-12 | Press release | Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposi |
| 2025-02-10 | Press release | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 |
| 2024-12-24 | Press release | Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit |